# Contact — Safe Tirzepatide

> Contact the Safe Tirzepatide editorial team. For editorial questions, citation corrections, and feedback on our Tirzepatide research digest. We do not provide medical advice.

## Get in touch

Safe Tirzepatide is an independent editorial project. We welcome messages on the following topics:

**Citation corrections or updates** — If you have identified a citation error, a broken DOI, or a more recent publication that supersedes a claim on this site, we want to know. This is how the digest stays accurate. Please include the page, the claim, and the suggested correction or replacement citation.

**Editorial feedback** — If a passage is unclear, jargon-heavy without adequate glossing, or otherwise difficult to read, that is useful to hear. The goal is a research digest that a curious non-specialist can navigate.

**New research** — If a 2024–2025 tirzepatide study, meta-analysis, or pharmacovigilance report should be indexed on this site and is not yet covered, feel free to flag it with the citation details.

What we do not handle: medical or clinical questions, requests for prescriptions or sourcing guidance, commercial inquiries, or link-exchange requests. This site does not provide medical advice.

## A note on medical questions

We are an editorial publisher, not a healthcare provider. If you have questions about whether tirzepatide is appropriate for you, dosing, or management of side effects, those questions belong with a licensed healthcare provider who can review your full medical history. This site documents the published research record; it cannot and does not substitute for clinical evaluation.

---

A newsroom reading of the tirzepatide safety record — the 2024–2025 trials and meta-analyses set down and cited, with no clinic, no prescriber, and no verdict on any individual's risk.